Abstract: The invention relates to a pharmaceutical composition comprising one or more stimulators of soluble guanylate cyclase (sGC), or a combination of at least one stimulator of sGC and at least one activator of sGC, for use in a method of treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3?,5?-guanosine monophosphate in the patient to be treated. The invention also relates to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. The invention also relates to a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator, for use in a method for the treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3?,5?-guanosine monophosphate in the patient to be treated.

Abstract: The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeutic combination for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury. The invention also relates to a pharmaceutical composition comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist, and to said pharmaceutical composition for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury.